CD274 and non-small cell lung carcinoma: Up to now, DDR gene alterations, especially deleterious alternations, have been demonstrated to be associated with improved clinical outcomes in metastatic urothelial cancer (26), metastatic clear cell renal cell carcinoma (27), and non-small-cell lung cancer (28) treated with PD-(L)1 inhibitors.